16 September 2014

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 12 September 2014 it granted options over a total of 580,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.

Director Number
of options
granted
Exercise
price
Exercise
period
Total number
of options
held following
notification
Total number
of ordinary
shares held
           
J H Barder 250,000 51.75p 1 Oct 2016 - 30 Sep 2021 1,250,000 1,008,830
D B Davies 200,000 51.75p 1 Oct 2016 - 30 Sep 2021 980,000 751,306
D A Martin 130,000 51.75p 1 Oct 2016 - 30 Sep 2021 719,279 280,000

All options were granted under the Futura Medical plc Unapproved Share Option Scheme with the exception of 103,961 options granted to D A Martin which were granted under the Futura Medical plc Enterprise Management Incentive Scheme.

The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com